Search Results

The KRONUS IA-2 Autoantibody (IA-2Ab) ELISA Kit is for the qualitative determination of antibodies to Islet Antigen-2 (IA-2) in human serum. The KRONUS IA-2 Autoantibody (IA-2Ab) ELISA Kit may be useful as an aid in the diagnosis of Type 1 diabetes mellitus (autoimmune mediated diabetes). The KRONUS IA-2 Autoantibody (IA-2Ab) ELISA Kit is not to be used alone and is to be used in conjunction with other clinical and laboratory findings.

Not Found

This document is an FDA clearance letter for an in vitro diagnostic (IVD) device, specifically an ELISA kit. It does not contain information about an AI/ML-driven medical device study or its performance characteristics. Thus, most of the requested information regarding acceptance criteria, study design, ground truth establishment, and expert involvement for an AI medical device cannot be extracted from this document.

The document discusses the clearance of the KRONUS IA-2 Autoantibody (IA-2Ab) ELISA Kit (K220085) for the qualitative determination of antibodies to Islet Antigen-2 (IA-2) in human serum, to be used as an aid in the diagnosis of Type 1 diabetes mellitus.

Therefore, I cannot provide the requested information based on the provided text. The questions are specifically tailored for an AI/ML device study, not for an ELISA kit's regulatory clearance.

Ask a specific question about this device

The KRONUS Steroid 21-Hydroxylase Autoantibody (21-OHAb) ELISA Kit is for the qualitative determination of antibodies to steroid 21-hydroxylase (21-OH) in human serum. The Steroid 21-Hydroxylase Autoantibody (21-OHAb) ELISA Kit is useful as an aid in the diagnosis of autoimmune adrenal disease, whether expressed as autoimmune Addison's disease (isolated) or Addison's disease as part of the more complex autoimmune polyglandular syndrome (APS), type I or II. The assay result is to be used in conjunction with other clinical and laboratory findings and is not a substitute for functional testing required to diagnose adrenal insufficiency.

Not Found

I am sorry, but the provided text only contains an FDA approval letter and an "Indications for Use" statement for the KRONUS Steroid 21-Hydroxylase Autoantibody (21-OHAb) ELISA Kit. It does not contain any information regarding acceptance criteria, study details, sample sizes, ground truth establishment, or expert qualifications for a device performance study.

Therefore, I cannot fulfill your request to describe the acceptance criteria and the study that proves the device meets them based on the given text.

Ask a specific question about this device

The KRONUS IA-2 Autoantibody (IA-2Ab) ELISA Kit is for the quantitative determination of antibodies to Islet Antigen-2 (IA-2) in human serum. The KRONUS IA-2 Autoantibody (IA-2Ab) ELISA Kit may be useful as an aid in the diagnosis of Type 1 diabetes mellitus (autoimmune mediated diabetes). The KRONUS IA-2 Autoantibody (IA-2Ab) ELISA Kit is not to be used alone and is to be used in conjunction with other clinical and laboratory findings.

Not Found

The provided text is an FDA 510(k) clearance letter for the KRONUS IA-2 Autoantibody (IA-2Ab) ELISA Kit. This letter confirms that the device has been reviewed and determined to be substantially equivalent to legally marketed predicate devices.

However, the letter does not contain any information about the acceptance criteria, study design, or performance data for the KRONUS IA-2 Autoantibody (IA-2Ab) ELISA Kit. It merely states the device's indications for use and general regulatory information.

Therefore, I cannot provide the requested information, including:

1. A table of acceptance criteria and reported device performance.
2. Sample sizes used for test sets or data provenance.
3. Number of experts or their qualifications for ground truth establishment.
4. Adjudication method.
5. Information on multi-reader multi-case (MRMC) comparative effectiveness studies.
6. Information on standalone (algorithm only) performance studies.
7. The type of ground truth used.
8. The sample size for the training set.
9. How ground truth for the training set was established.

This type of detailed study information is typically found in the 510(k) submission itself (which is not provided here) or in accompanying technical documentation or scientific publications, not in the clearance letter. The letter is the outcome of the review process, not the detailed report of the review findings.

Ask a specific question about this device

The KRONUS Aquaporin-4 Autoantibody (AQP4Ab) ELISA Assay is for the semi-quantitative determination of autoantibodies to Aquaporin-4 in human serum. The KRONUS Aquaporin-4 Autoantibody (AQP4Ab) ELISA Assay may be useful as an aid in the diagnosis of Neuromyelitis Optica (NMO) and Neuromyelitis Optica Spectrum Disorders (NMOSD). The KRONUS Aquaporin-4 Autoantibody (AQP4Ab) ELISA Assay is not to be used in conjunction with other clinical, laboratory, and radiological (e.g. MRI) findings.

Not Found

This is a 510(k) premarket notification for an in vitro diagnostic (IVD) device, not an AI/ML medical device. Therefore, many of the requested categories for AI/ML device studies are not applicable.

Here's an attempt to answer the questions based on the provided text, primarily focusing on the device itself and applicable sections:

1. A table of acceptance criteria and the reported device performance
   The provided text is a letter from the FDA acknowledging the substantial equivalence of the device and contains the Indications for Use. It does not include specific acceptance criteria or performance data tables. For IVD devices, such data would typically be found in the 510(k) summary or the full submission, which is not part of this document.

2. Sample size used for the test set and the data provenance (e.g., country of origin of the data, retrospective or prospective)
   This information is not provided in the supplied FDA letter or Indications for Use statement.

3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts (e.g., radiologist with 10 years of experience)
   This information is not applicable and not provided. The device is an ELISA assay for autoantibodies, and ground truth for such assays would typically be established by clinical diagnosis and/or correlation with other lab tests, not by expert interpretation of images/data in the same way as an imaging AI device.

4. Adjudication method (e.g., 2+1, 3+1, none) for the test set
   This information is not applicable and not provided.

5. If a multi-reader multi-case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance
   This information is not applicable. The device is an IVD ELISA assay, not an AI-assisted diagnostic tool that humans would use to interpret cases.

6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done
   This information is not applicable. The device is a laboratory assay. Its performance is evaluated intrinsically through analytical and clinical studies, not typically as an "algorithm only" or "human-in-the-loop" system in the context of AI.

7. The type of ground truth used (expert consensus, pathology, outcomes data, etc.)
   The device is an assay for autoantibodies to Aquaporin-4 (AQP4Ab) to aid in the diagnosis of Neuromyelitis Optica (NMO) and Neuromyelitis Optica Spectrum Disorders (NMOSD). The "ground truth" for evaluating such a diagnostic aid would typically be the definitive clinical diagnosis of NMO/NMOSD based on established diagnostic criteria, which may involve a combination of clinical presentation, neurological examination, imaging (e.g., MRI findings), and other laboratory tests. The device itself is designed to contribute to this diagnosis.

8. The sample size for the training set
   This information is not provided in the supplied FDA letter or Indications for Use statement. For an IVD assay development, a "training set" might refer to samples used for assay optimization and cutoff determination, but specific details are not given here.

9. How the ground truth for the training set was established
   This information is not provided. Similar to the test set, any "training set" for an IVD assay would likely use confirmed clinical diagnoses for NMO/NMOSD as the ground truth.

Ask a specific question about this device

The KRONUS Aquaporin-4 Autoantibody (AQP4Ab) ELISA Assay is for the semiquantitative determination of autoantibodies to Aquaporin-4 in human serum. The KRONUS Aquaporin-4 Autoantibody (AQP4Ab) ELISA Assay may be useful as an aid in the diagnosis of Neuromyelitis Optica (NMO) and Neuromyelitis Optica Spectrum Disorders (NMOSD). The KRONUS Aquaporin-4 Autoantibody (AQP4Ab) ELISA Assay is not to be used alone and is to be used in conjunction with other clinical, laboratory, and radiological (e.g., MRI) findings.

The KRONUS Aquaporin-4 Autoantibody (AQP4Ab) ELISA Assay consists of ELISA strip wells coated with human recombinant AQP4 protein (amino acid position: 23-323) (96 wells in total) and supplied as 12 strips of 8 wells in a frame and sealed in a foil pouch with desiccant; ready-to-use 5 levels of calibrators (1.5, 5, 20, 40, and 80 U/mL), 5 x 0.7 mL; a ready-to-use positive (2 x . 7 mL) and a negative control serum (1 x 0.7 mL); AQP4-Biotin (lyophilized), 3 x 1.5 mL (reconstituted); ready-to-use reconstitution buffer for AQP4-Biotin, 1 x 10 mL; Streptavidin Peroxidase (SA-POD dilute before use) 1 x 0.8 mL; ready-to-use diluent for SA-POD, 1 x 15 mL; ready-to-use peroxidase substrate (TMB), 1 x 15 mL; concentrated wash solution (dilute 1:10 with deionized water before use), 1 x 120 mL and ready-to-use stop solution, 1 x 14 mL.

KRONUS Aquaporin-4 Autoantibody (AQP4Ab) ELISA Assay: Acceptance Criteria and Performance Study

This document summarizes the acceptance criteria and the study demonstrating the KRONUS Aquaporin-4 Autoantibody (AQP4Ab) ELISA Assay meets these criteria, based on the provided text.

1. Table of Acceptance Criteria and Reported Device Performance

The provided text focuses on the performance characteristics of the KRONUS Aquaporin-4 Autoantibody (AQP4Ab) ELISA Assay. While explicit "acceptance criteria" are not always presented as a direct numerical threshold in this document, the studies demonstrate that the device's performance metrics were "within the manufacturer's pre-determined acceptance limit" or "deemed appropriate" based on the established cut-off. The table below compiles the reported performance metrics.

Ask a specific question about this device